News
Academy
Editorial PodcastsEditorial VideosProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Pharmaceutical Executive APEX Awards
  • Latest Executive Roundtables
  • Asembia 2025
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Prove It! Top Line Thoughts on Trends That Will Shape the Industry in 2014

January 9, 2014
By Guest Blogger
Article

Pharmaceutical Executive

Ten days in and the New Year already seems old. Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets.

Ten days in and the New Year already seems old.  Yet members of our Pharm Exec Editorial Advisory Board are still eager to share their top of line predictions on trends that will shape the industry’s business and reputational assets – forward and backward – over the busy months ahead.   Here, one of our best external-facing experts weighs in.

According to Board member and investment analyst Les Funtleyder, three themes dominate.

The first is a big strategic question:  do you divest businesses and narrow the focus on R&D or stay the course on asset diversification, maintaining that big in-house development pipeline?  Clear lines of demarcation are emerging; this year will provide some proof points as to which strategy proves right.   Will BMS and Pfizer outperform Merck and Lilly by doubling down on core assets and divesting areas that pose too much front-end R&D risk?

The second is the prospect for more upside potential in biotech, where rising valuations over the past 18 months – and a 7 per cent surge already this year – have strengthened the segment’s hand in its traditionally dependent relationship with Big Pharma.  Is the run-up akin to a bubble and, if so, is it prone to bursting?  That prospect is unlikely, given that much of the valuation gain is concentrated in mid-size “stealth pharma” leaders like Celgene and Gilead, whose market caps have soared, while smaller start-ups still face barriers to raising capital, including an indifferent climate for biotech IPOs.

What really matters is the politics of this valuation gap, as it adds to pressure on Big Pharma CEOs to explain why their own performance isn’t meeting the mark set by biotech’s stars.   “How CEOs respond will be an interesting story in 2014,” says Funtleyder.  “I see three choices – to buy their way to higher valuations through targeted biotech acquisitions; placing more bets on process innovations, adding services beyond the pill; or playing the emerging markets card with more investments in the BRICS and high growth second-tier Asian countries.”

Funtleyder’s third theme is the scrutiny that comes from the impact of technology and social media – specifically, how the glare of transparency no longer allows companies to hide flaws that in earlier times could be safely papered over or ignored. “The proliferation of data, its accuracy, and the ability to access and interpret it at every level of the organization has altered basic norms of behavior in the marketplace,” says Funtleyder.

While transparency carries with it significant efficiency gains by improving the capacity of customers to choose wisely, there is a big downside:  less context, and an undue assumption of certainty which puts more onus on companies to explain and communicate both the benefits and the limits of this data.  Expect more actions like the FDA decision to restrict advocacy organizations like 23andMe from providing patients with details of their individual genetic profiles, on grounds that such data may be misinterpreted, with possibly damaging implications for individual health.  “It raises the issue of what you can or should do with this data – the pace of technology is beginning to exceed the capacity of governments to regulate it,” Funtleyder observes.

His one piece of cautionary advice for 2014 is to start preparing now for a surge in conflict-of-interest challenges, because every functional activity is going to get the once over from motivated, self-interested outside parties determined to tap big data’s expanding ability to identify, assess, test, uncover and anticipate.  “Prove It” is the mantra for pharma in 2014.

Recent Videos
Related Content

Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Don Tracy, Associate Editor
May 15th 2025
Article

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Stock.adobe.com

NAMI Responds to Potential Cuts to Medicaid

Mike Hollan
May 15th 2025
Article

The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Stock.adobe.com

Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

Partha Anbil;Kamini Anbil
May 15th 2025
Article

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.


Reshema Kemps-Polanco: Taking Risks for Greater Reward

Reshema Kemps-Polanco: Taking Risks for Greater Reward

Mike Hollan
May 14th 2025
Article

Reshema Kemps-Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of the Year, uses the lessons she learned from her family to bring out the best in her teams.

Related Content

Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Novo Nordisk, Septerna Enter Global Collaboration to Develop Cardiometabolic Medicines

Don Tracy, Associate Editor
May 15th 2025
Article

The collaboration will launch four development programs targeting key G protein-coupled receptors—GLP-1, GIP, and glucagon—to develop oral cardiometabolic medicines.


Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
April 14th 2025
Podcast

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.


Stock.adobe.com

NAMI Responds to Potential Cuts to Medicaid

Mike Hollan
May 15th 2025
Article

The organization believes that the proposed cuts will be harmful to Americans suffering from mental illnesses.


Beyond the Prescription: Pharma's Role in Digital Health Conversations

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
April 1st 2025
Podcast

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.


Stock.adobe.com

Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

Partha Anbil;Kamini Anbil
May 15th 2025
Article

The window of opportunity for launch is short and unforgiving, and the success depends on flawless execution of launch activity across countries and functions.


Reshema Kemps-Polanco: Taking Risks for Greater Reward

Reshema Kemps-Polanco: Taking Risks for Greater Reward

Mike Hollan
May 14th 2025
Article

Reshema Kemps-Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of the Year, uses the lessons she learned from her family to bring out the best in her teams.

About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.